Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 58c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $247.72 +1.45%
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
HELE, PSMT, LEVI, More
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
HELE, PSMT, LEVI, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.21, $0.58 better than the analyst estimate of $3.63. Revenue for the quarter came in at $892.88 million versus the consensus estimate of $865.88 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2022 EPS of $16.00-$17.00, versus the consensus of $17.47.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
- Goldman Sachs Starts Banco de Sabadell SA (SAB:SM) (BNDSF) at Sell
- Goldman Sachs Downgrades Banco Comercial Portugues (BCP:LI) (BPCGF) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
